Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer.
about
Natural Polyphenols for Prevention and Treatment of Cancer(-)-Epigallocatechin-3-Gallate Inhibits Colorectal Cancer Stem Cells by Suppressing Wnt/β-Catenin PathwayHow Diet Intervention via Modulation of DNA Damage Response through MicroRNAs May Have an Effect on Cancer Prevention and Aging, an in Silico Study.Gankyrin sustains PI3K/GSK-3β/β-catenin signal activation and promotes colorectal cancer aggressiveness and progression.Ectopic overexpression of CD133 in HNSCC makes it resistant to commonly used chemotherapeutics.Recent progress on the effects of microRNAs and natural products on tumor epithelial-mesenchymal transition.Therapeutic Potential of Epigallocatechin Gallate Nanodelivery SystemsProton pump inhibitors increase the chemosensitivity of patients with advanced colorectal cancer.miR-34a mediates oxaliplatin resistance of colorectal cancer cells by inhibiting macroautophagy via transforming growth factor-β/Smad4 pathwayEpigallocatechin-3-gallate induces apoptosis in acute promyelocytic leukemia cells via a SHP-1-p38α MAPK-Bax cascade.Human cancer stem cells are a target for cancer prevention using (-)-epigallocatechin gallate.MACC1 facilitates chemoresistance and cancer stem cell‑like properties of colon cancer cells through the PI3K/AKT signaling pathway.Chemoresistance to 5-FU inhibited by 635 nm LED irradiation in CD133+ KB cell line.NEAT1 acts as an inducer of cancer stem cell-like phenotypes in NSCLC by inhibiting EGCG-upregulated CTR1.Overexpression of miR-489 enhances efficacy of 5-fluorouracil-based treatment in breast cancer stem cells by targeting XIAP.Oligomeric proanthocyanidins (OPCs) target cancer stem-like cells and suppress tumor organoid formation in colorectal cancer.Cancer Prevention with Green Tea and Its Principal Constituent, EGCG: from Early Investigations to Current Focus on Human Cancer Stem Cells.Cancer stem cells in progression of colorectal cancermiR-34a Regulates Multidrug Resistance via Positively Modulating OAZ2 Signaling in Colon Cancer Cells
P2860
Q26739022-887405F7-6B0D-47BF-85E7-378957D8F1A6Q33851929-FA3D97D0-EE43-4156-B371-69310E6EFA81Q36939317-5FF1ECA7-1445-42E4-9B6A-545AF4AFB6A1Q37697139-06486EF4-5762-40E0-922F-BBA0F0A913E3Q38404080-ABB0BE25-70AE-4C66-A59A-B5F583CA6528Q39458257-F5CD120C-5190-4D0E-B3F4-EE029943C478Q41169121-608E5DB4-BCBD-46E2-A40F-55690B0B88EBQ41709117-21D26A30-E89B-4793-BB0A-0D640898E14BQ42316098-1AA21468-25BC-4748-80EE-81177D6F2F56Q46094753-9010DF38-27E1-433F-B679-1E05C6D07F4FQ47133638-62D59722-3E78-47D2-AE1F-62496DFFD1BAQ47679757-05904C6F-FCA6-4B68-BC5F-709F4E708168Q47732905-3624AAE3-EB06-456A-BFAA-E2868FD698E8Q48274541-A88D73AD-04E1-4B15-B2EE-B4167C0296EEQ48523013-35DA0DF2-6BD0-49BB-8984-282934B35E5EQ49789755-23F0EB04-99B5-4A08-9CEE-D81A3A1C54D8Q50078680-585996A0-8FBE-441C-AA22-60DF382B8139Q57150975-EADBBF37-0434-4393-9093-E8F42D5E76D3Q58802988-8995E0F2-60D9-4AF2-ABF1-066978132D78
P2860
Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 22 February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Epigallocatechin-3-gallate tar ...... sitivity in colorectal cancer.
@en
Epigallocatechin-3-gallate tar ...... sitivity in colorectal cancer.
@nl
type
label
Epigallocatechin-3-gallate tar ...... sitivity in colorectal cancer.
@en
Epigallocatechin-3-gallate tar ...... sitivity in colorectal cancer.
@nl
prefLabel
Epigallocatechin-3-gallate tar ...... sitivity in colorectal cancer.
@en
Epigallocatechin-3-gallate tar ...... sitivity in colorectal cancer.
@nl
P2093
P2860
P356
P1433
P1476
Epigallocatechin-3-gallate tar ...... sitivity in colorectal cancer.
@en
P2093
Hanh-My Tran
Oscar A Tovar-Camargo
Shusuke Toden
Yoshinaga Okugawa
P2860
P304
16158-16171
P356
10.18632/ONCOTARGET.7567
P407
P50
P577
2016-02-22T00:00:00Z